GENE ONLINE|News &
Opinion
Blog

2021-08-24| Special

The 6 Companies Leading the Resurgence in RNA Editing R&D

by Tyler Chen
Share To
Despite the transcending advance of CRISPR gene editing, interest in RNA editing is slowly catching on. A handful of companies are now launching projects banking on innovative technologies to draw investor attention.

Current research endeavors focus on the applications of the human RNA editing enzymes called ADARs (adenosine deaminase act on double-stranded RNA). ADAR enlists the help of guide RNA (gRNA), which shuttles it to a target location to carry out precise and efficient editing.

Here is our list of six companies and their research indications, target areas, and fundraising power to bring you up to speed on the frontrunners of a growing industry. GeneOnline lists emerging RNA editing companies that are set to make a mark in 2021

GO Prime with only $1.49 now

LATEST
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
EVENT
Scroll to Top